News
Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis
July 25, 2014 | Press ReleaseGalectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02 in Combination with Ipilimumab in Metastatic Melanoma
July 22, 2014 | Press ReleaseGalectin Therapeutics Added to Russell 2000 Index
July 9, 2014 | Press ReleaseClick here to view a presentation with findings from cohort 2 of a phase 1 clinical trial of GR-MD-02 in fatty liver disease with advanced fibrosis.
Highlights
View a New York Times article highlighting Galectin Therapeutics’ role in the fight against fatty liver disease
June 16, 2014 | News ArticleView a video recording of the 2014 Annual Stockholder Meeting
May 21, 2014 | WebcastView a presentation from the 2014 Annual Stockholder Meeting
May 14, 2014 | Presentation
Galectin Therapeutics, Inc.
NASDAQ: GALT
5.64-8.90 Stock price updates every 30 minutes.